Show summary Hide summary
New research suggests that lifesaving cancer treatments given to children and young adults can leave a measurable imprint on cellular aging — and that this accelerated aging is linked to lasting problems with memory and attention. For survivors who may live for decades after treatment, the findings raise fresh questions about long-term care and monitoring.
The study, led by investigators at the University of Rochester Medical Center, assessed blood samples from roughly 1,400 long-term survivors treated at St. Jude Children’s Research Hospital. Scientists applied epigenetic clocks — molecular tools that estimate a person’s biological age by reading chemical marks on DNA — to determine whether therapies are associated with an older-than-expected cellular profile.
Iran crisis raises immediate risks: Trump’s oil-first foreign policy in jeopardy
Aroma Park mass draws community and faith leaders: photos from the gathering
What the data showed
Researchers compared the epigenetic age of survivors with their chronological age and then related those measures to results from cognitive tests that evaluated attention, memory and information processing speed. The cohort included mainly survivors of acute lymphoblastic leukemia and Hodgkin lymphoma, all at least five years post-treatment.
- Survivors with a higher epigenetic or biological age tended to perform worse on tests of memory and attention.
- Chemotherapy was the treatment most strongly associated with accelerated biological aging in the blood samples.
- The research found a consistent link between markers of cellular aging and cognitive performance, though it could not establish direct causation.
Investigators note the pattern mirrors observations in older adults, where age-related epigenetic changes have been tied to declines in domains commonly affected by dementia and normal aging. The new analysis suggests similar processes may be triggered or amplified by cancer therapies received much earlier in life.
Possible mechanisms and clinical context
Laboratory and clinical evidence indicates that certain chemotherapeutic agents can damage DNA and other cellular structures. That damage may accelerate the accumulation of molecular marks normally associated with aging, and clinicians have long observed a constellation of cognitive complaints after treatment — often described informally as “chemo brain.”
An oncology specialist not involved with the study said the findings align with clinical experience: treatments targeting fast-dividing cancer cells also affect normal tissue, and the resulting cellular stress can show up as persistent cognitive symptoms.
Limitations and next steps
The authors acknowledge key constraints. The study was cross-sectional — it measured survivors at a single point in time — so it cannot prove that treatment directly caused the accelerated aging. Researchers also did not adjust for some later-life factors, such as chronic health conditions or educational attainment, because those outcomes may themselves stem from treatment and would complicate causal interpretation.
Still, the team sees the findings as a roadmap for further work. Lead author AnnaLynn Williams, PhD, said researchers want to identify when these aging markers first appear and whether early interventions could alter a survivor’s long-term trajectory. The ultimate goal is to preserve both lifespan and quality of life for people treated in childhood and young adulthood.
Why this matters now
There are more long-term survivors today than in previous decades, thanks to advances in pediatric oncology. That creates an urgent need to understand late effects of treatment that may only become apparent decades later. If validated in follow-up studies, epigenetic measures could help target surveillance and preventive strategies earlier in survivorship care.
The study appears in Nature Communications and adds to a growing literature exploring how cancer therapies intersect with biological aging. Future research will need longitudinal sampling and a closer look at which specific treatments, doses or combinations pose the greatest risks — and which interventions might blunt or reverse those molecular signals.
